Semaglutide vs Tirzepatide vs Retatrutide vs Orforglipron: Receptor Profiles Compared

Semaglutide, tirzepatide, retatrutide, and orforglipron are all GLP-1R agonists — but they differ significantly in receptor selectivity, molecular class, route of administration, and clinical weight reduction magnitude. This comparison covers the mechanistic distinctions that matter for research design.

Receptor Profiles at a Glance

Semaglutide — The Reference Peptide GLP-1R Agonist

Semaglutide is a GLP-1 analog with ~94% sequence homology to native GLP-1, extended with a C18 fatty acid chain enabling albumin binding and a half-life of ~7 days. It is the most extensively studied and most widely approved GLP-1R agonist, providing the reference dataset against which newer compounds are benchmarked. For research requiring an established, selective peptide GLP-1R agonist with the largest clinical evidence base, semaglutide remains the primary comparator.

Tirzepatide — Dual GLP-1R + GIPR Agonist

Tirzepatide is a synthetic 39-amino acid peptide engineered as a balanced dual agonist at GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). The GIPR component provides additive insulin secretion stimulation and independently activates adipose lipolysis and energy expenditure pathways that GLP-1R does not directly engage. The SURMOUNT Phase 3 program documented ~20–22% mean body weight reduction — exceeding semaglutide — attributed to the additive GLP-1R + GIPR signalling. For research specifically examining the GIP receptor contribution to metabolic outcomes, tirzepatide is the primary tool.

Retatrutide — Triple GLP-1R + GIPR + GCGR Agonist

Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1R + GIPR dual agonism of tirzepatide. Glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and lipolysis — pathways complementary to but mechanistically distinct from GLP-1R and GIPR signalling. Phase 2 data showed ~24% mean body weight reduction at 48 weeks — the highest in a clinical trial at the time of publication. Retatrutide is the research tool of choice for studying the maximum achievable metabolic effect of GLP-1 axis agonism and for dissecting the relative contributions of each receptor to observed outcomes through selective antagonist studies.

Orforglipron — Oral Non-Peptide Selective GLP-1R Agonist

Orforglipron occupies a unique position: the only oral, non-peptide, selective GLP-1R agonist in the group. Its ~8–15% weight reduction in Phase 3 (ATTAIN) is lower than injectable agonists at equivalent clinical doses, but its oral once-daily administration without fasting requirements changes the research question entirely. For mechanistic research on allosteric vs orthosteric GLP-1R activation, oral vs injectable administration effects, or patient adherence studies, orforglipron is the appropriate tool. For maximum weight reduction magnitude in metabolic efficacy studies, retatrutide or tirzepatide remain preferable.

Choosing the Right Compound for Your Research

The optimal compound depends on the specific mechanistic question. Use semaglutide as the GLP-1R reference when comparing against established clinical outcomes. Use tirzepatide when GIP receptor involvement is the variable of interest. Use retatrutide for maximum metabolic effect or GIP+GCG receptor research. Use orforglipron for oral GLP-1R agonism, allosteric pharmacology, or comparative oral vs injectable administration studies.